The Phase I/II China-based trial will test the combination in patients with PD-L1-positive, EGFR mutated tumors.
The European Commission has approved Novartis' gene therapy Itvisma (onasemnogene abeparvovec) for patients at least two years old with 5q-associated spinal muscular atrophy (SMA) and biallelic SMN1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results